Severe acute respiratory infection risk following glucocorticosteroid treatment in uncomplicated influenza-like illness resulting from pH1N1 influenza infection: a case control study

Table 4 Drugs used to treat influenza-like illness (ILI) from pH1N1 influenza, before sARI onset in 50 severe acute respiratory infection (sARI) cases and during equivalent period after ILI onset in 79 controls

Drugs	Number exposed		Percent exposed		Matched odds ratio^a (95%CI)
Drugs	Case (N = 50)	Control (N = 79)	Case	Control	Matched odds ratio^a (95%CI)
Glucocorticosteroids^b before sARI onset	17	3	34.0	3.8	17.0(2.1–135.0)
Glucocorticosteroids^b before both pneumonia and SARI	15	2	30.0	2.5	15.0(1.9–120.9)
Pyrazolones^c	13	5	26.0	6.3	3.0(0.8–11.7)
Neuraminidase inhibitor	4	6	8.0	7.6	0.6(0.1–3.4)
Amantidine	3	4	6.0	5.1	0.3(0.0–2.8)
Ribavirin	21	32	42.0	41	1.3(0.5–3.2)
Other antivirals	6	11	38.8	61.2	0.5(0.1–2.5)
Antibiotics	43	63	86.0	79.7	0.8(0.2–2.6)
Acetaminophen	14	12	28.0	15.2	–
Ibuprofen	11	15	22.0	19.0	0.8(0.2–2.8)
Nimesulide	9	15	18.0	19.0	1.4(0.4–4.4)
Traditional Chinese medicine	28	51	56.0	64.6	1.6(0.7–3.4)

^aOdds Ratio is matched by age group and underlying disease, ^bdexamethasone or methyl prednisolone, ^caminopyrine or dipyrone

ISSN: 1471-2334